Should Investors Be Worried About Editas' Share Decline?

Brian Orelli, PhD and Keith Speights, The Motley Fool
·3 min read

In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the recent downturn in Editas Medicine's (NASDAQ: EDIT) stock price and the biotech's change in management. Brian Orelli: Teresa asks if we could talk about the recent news on management changes, and then somebody else said should Editas be put in the penalty box as of late, the performance has been terrible, ticker there is EDIT. Keith Speights: Their CEO change was unexpected, at least to me.